GlassScriptPhysician profile
Jared Hamm
NPI 1588984561
$740.03
in general payments reported to CMS, 2019-2025
16 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Clinical Biochemical Genetics provider received nationally (typical 2025 total: $237).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.77 · 2022: $93.88 · 2023: $169 · 2024: $14.04 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.38 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zevra Therapeutics INC | $140.51 | 2025 | Olpruva |
| Genzyme Corporation | $138.21 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.95 | 2023-2025 | Vpriv, Elaprase |
| Biogen, INC. | $55.84 | 2021-2023 | Spinraza |
| Alexion Pharmaceuticals, INC. | $52.42 | 2022-2025 | |
| Cycle Pharmaceuticals INC | $37.82 | 2025 | Javygtor, Nityr |
| Sanofi-Aventis U.S. LLC | $35.77 | 2021 | |
| Ptc Therapeutics, INC. | $31.29 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $30.00 | 2023 | Dojolvi |
| Novartis Pharmaceuticals Corporation | $28.09 | 2025 | |
| Recordati_rare_diseases_inc. | $24.87 | 2021 | |
| Soleno Therapeutics, INC. | $17.57 | 2025 | Vykat Xr |
| Horizon Therapeutics Plc | $17.41 | 2022 | |
| Ns Pharma, INC. | $16.18 | 2021 | |
| Travere Therapeutics, INC. | $14.10 | 2023 | Cholbam |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Hamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.